Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC) Phase II Trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 4, 2018, Pages 332-338

  Pokuri, Venkata K ^a   Tomaszewski, Garin M ^b   Ait Oudhia, Sihem ^h   Groman, Adrienne ^c   Khushalani, Nikhil I ^a   Lugade, Amit A ^a   Thanavala, Yasmin ^d   Ashton, Edward A ^g   Grande, Catherine ^e   Fetterly, Gerald J ^f   Iyer, Renuka ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Departments of Interventional Radiology   (United States)

^c Departments of Biostatistics   (United States)

^d Departments of Immunology and Pathology   (United States)

^e Departments of Clinical Research Services   (United States)

^f School of Pharmacy   (United States)

^g VirtualScopics LLC   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

Author keywords

biomarkers; dynamic contrast enhanced magnetic resonance imaging; hepatocellular carcinoma; liver directed therapy; quality of life; sunitinib; transarterial chemoembolization

Indexed keywords

AMYLASE; BIOLOGICAL MARKER; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; N DEETHYLSUNITINIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL LIPASE; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; DISEASE COURSE; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IC50; INOPERABLE CANCER; LIMIT OF DETECTION; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MEDIAN SURVIVAL TIME; MONOCYTE COUNT; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; CLINICAL TRIAL; LIVER TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SUNITINIB; SURVIVAL RATE;

EID: 84961566836     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000286     Document Type: Article

References (40)

1. Benson AB III, DAngelica MI, Abrams TA, et al. Hepatobiliary cancers, version 2.2014. J Natl Compr Cancer Netw. 2014;12: 1152-1182.
2. Yao DF, Wu XH, Zhu Y, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2005;4:220-226.
3. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-4300.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
6. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-896.
7. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study. Lancet Oncol. 2009;10: 794-800.
8. Koeberle D, Montemurro M, Samaras P, et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15: 285-292.
9. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol. 2009;27: 3027-3035.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology (Baltimore, MD). 2011;53:1020-1022.
11. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet (London, England). 2002;359:1734-1739.
12. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (Baltimore, MD). 2002;35: 1164-1171.
13. Shim JH, Park JW, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008;99:2037-2044.
14. Xiong ZP, Yang SR, Liang ZY, et al. Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2004;3:386-390.
15. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007;13:2643-2650.
16. Zhu AX, Duda DG, Sahani DV, et al. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009;15:263-268.
17. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067-4075.
18. Kepner JL, Chang MN. Samples of exact k-stage group sequential designs for phase II and pilot studies. Control Clin Trials. 2004;25:326-333.
19. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005;23:5464-5473.
20. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24: 25-35.
21. Roskoski R Jr. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356:323-328.
22. Lin ZY, Chuang WL. High therapeutic concentration of prazosin up-regulates angiogenic IL6 and CCL2 genes in hepatocellular carcinoma cells. Biomed Pharmacother. 2012;66:583-586.
23. Castermans K, Tabruyn SP, Zeng R, et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood. 2008;112: 4940-4947.
24. Kalathil S, Lugade AA, Miller A, et al. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloidderived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013;73:2435-2444.
25. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003;21: 3955-3964.
26. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24: 769-777.
27. Hsu CY, Shen YC, Yu CW, et al. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol. 2011;55: 858-865.
28. Yau T, Chen PJ, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011;17:6914-6923.
29. den Brok MH, Sutmuller RP, Nierkens S, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-Tumour immunity. Br J Cancer. 2006;95:896-905.
30. Liao J, Xiao J, Zhou Y, et al. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol Med Rep. 2015;12:6065-6071.
31. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A. 2005;102:419-424.
32. Qin Z, Schwartzkopff J, Pradera F, et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8 + T cells. Cancer Res. 2003;63:4095-4100.
33. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69:2514-2522.
34. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008;111:5610-5620.
35. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14:6674-6682.
36. Liu L, Chen H, Wang M, et al. Combination therapy of sorafenib and TACE for unresectable HCC: A systematic review and metaanalysis. PLoS One. 2014;9:e91124.
37. Cabibbo G, Tremosini S, Galati G, et al. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2014;14:831-845.
38. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, doubleblind SPACE trial. J Clin Oncol. 2012;30(Suppl 4): Suppl 4; abstr LBA154.
39. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (Oxford, England). 2011;47:2117-2127.
40. Chen J, Zhou C, Long Y, et al. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: A propensity score matching study. Tumour Biol. 2015;36:183-191.